XML 37 R23.htm IDEA: XBRL DOCUMENT v3.4.0.3
Collaboration and Other Agreements, Takeda (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended
May. 31, 2014
Mar. 31, 2016
Mar. 31, 2015
Dec. 31, 2015
Collaboration And Other Agreements [Line Items]        
Deferred revenue included in current liabilities   $ 4,919   $ 5,866
Deferred revenue included in long-term liabilities   $ 11,685   12,631
Takeda Pharmaceutical Company Limited [Member]        
Collaboration And Other Agreements [Line Items]        
Non-refundable upfront payment $ 15,000      
Takeda Pharmaceutical Company Limited [Member] | Research Collaboration And License Option Agreement [Member]        
Collaboration And Other Agreements [Line Items]        
Collaboration or other agreement date   September 2014    
Amount allocated to agreement 5,000      
Recognized revenue under agreement     $ 300  
Takeda Pharmaceutical Company Limited [Member] | Takeda MGD010 Agreement [Member]        
Collaboration And Other Agreements [Line Items]        
Collaboration or other agreement date   May 2014    
License option fee   $ 15,000    
Amount allocated to agreement $ 10,000      
Expected period of development   24 months    
Recognized revenue under agreement   $ 900 4,300  
Milestone received     $ 3,000  
Deferred revenue   1,100   2,100
Deferred revenue included in current liabilities   1,100   $ 2,100
Takeda Pharmaceutical Company Limited [Member] | Takeda MGD010 Agreement [Member] | Maximum [Member]        
Collaboration And Other Agreements [Line Items]        
Potential clinical and regulatory milestone payments   93,000    
Potential sales milestone payments under agreement   $ 375,500